Status:
TERMINATED
Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
Lead Sponsor:
Albert Einstein College of Medicine
Collaborating Sponsors:
Pancreatic Cancer Action Network
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18-100 years
Phase:
PHASE2
Brief Summary
The investigator is developing an immune therapy against pancreatic cancer. Immune cells, known as "T cells with tumor killing capacity", are involved in this immune therapy. In mice with pancreatic c...
Detailed Description
Treating PDAC patients with gemcitabine and one TT booster Gemcitabine will be delivered as is standard of care. However, doses may be modified by the treating physician based on patient tolerance. Pa...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed adenocarcinoma of the pancreas
- Patients is a candidate for gemcitabine chemotherapy (adjuvant, metastatic, locally advanced, borderline resectable settings all permitted)
- Patients at least 18 years of age
- ECOG performance status 0-2
- Consent to donate 12 tubes of peripheral blood of 10 mL each
- Adequate organ function as defined as -neutrophil count ≥ 1200 -platelets ≥ 75,000 -hemoglobin ≥ 8.0 -bilirubin ≤ 2.0 -creatinine ≤2.0 or calculated GFR ≥ 30
- Ability to understand and willingness to sign a written informed consent document
- Prior chemotherapy permitted, as long as 60 days have lapsed since last dose. Prior radiation therapy permitted, as long as 28 days lapsed since last treatment.
- Patients may receive other concurrent chemotherapy, immunotherapy, or radiotherapy
Exclusion
- Patients never been immunized with tetanus toxoid (TT). Patients with a history of adverse reaction to tetanus vaccine (with the exception of self-limited fever or local tissue reaction
- Patients may not be receiving any investigational agents
- Pregnant women
- Patients with HIV
Key Trial Info
Start Date :
July 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 11 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03848182
Start Date
July 21 2017
End Date
November 11 2019
Last Update
April 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Albert Einstein College of Medicine
The Bronx, New York, United States, 10461